Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

NCT ID: NCT01714947

Last Updated: 2018-10-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-24
• Study Completion Date: 2013-06-14

Brief Summary

The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.

Detailed Description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat participants who have advanced solid tumors or lymphomas. This study looked at mass balance, pharmacokinetics (PK), metabolism, elimination and safety of alisertib.

The study enrolled 3 patients. The study consisted of 2 parts: Part A and Part B. Participants received:

• [^14C]-alisertib 35 mg in Part A
• alisertib 50 mg in Part B

Participants were asked to take a single dose of [^14C]-alisertib oral solution containing 80-100 μCi of total radioactivity (1.19-1.48 mCi/mmol) in Part A and alisertib 50 mg, orally, twice daily for 7 days in 21-day cycles until disease progression or unacceptable toxicity in Part B.

This single center trial was conducted in United States. The overall time to participate in this study was up to 117 days. Participants remained confined to clinic in Part A and made multiple visits to the clinic in Part B. Participants were contacted 30 days after last dose of alisertib in Part A (if not continuing in Part B), or were contacted by telephone or a final visit 30 days after receiving their last dose of alisertib in Part B for a follow-up assessment.

Conditions

Advanced Solid Tumors; Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Alisertib

Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.

Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles).

Group Type: EXPERIMENTAL

[^14C]-alisertib

Intervention Type: DRUG

\[\^14C\]-alisertib oral solution

alisertib

Intervention Type: DRUG

Alisertib enteric coated tablets

Interventions

[^14C]-alisertib

\[\^14C\]-alisertib oral solution

Intervention Type: DRUG

alisertib

Alisertib enteric coated tablets

Intervention Type: DRUG

Other Intervention Names

MLN8237; MLN8237

Eligibility Criteria

Inclusion Criteria

• 18 years or older.
• Histologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment does not exist, or is no longer effective or tolerable.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Expected survival longer than 3 months from enrollment in the study.
• Radiographically or clinically evaluable tumor.
• Suitable venous access for the conduct of blood sampling.
• Recovered from the reversible effects of prior antineoplastic treatment (with the exception of alopecia and Grade 1 neuropathy).
• Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time.
• Male participants who agree to practice effective barrier contraception during the entire study and through 4 months after the last dose of study drug OR agree to abstain from heterosexual intercourse.

Exclusion Criteria

• Female participants who are lactating or have a positive serum pregnancy test.
• Treatment with any investigational products or systemic antineoplastic treatment within 21 days before the first dose of alisertib.
• Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors(PPIs) within 7 days preceding the first dose of alisertib, or H2-receptor antagonists within 24 hours preceding the first dose of alisertib.
• Participants requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose anticoagulation to maintain patency of venous access devices). Low molecular weight heparin, administered as preventive treatment, is allowed if the participant has tolerated treatment with a stable dose and schedule without bleeding complications for more than 1 month.
• Major surgery within the 14 days preceding the first dose of alisertib.
• Infection requiring systemic intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection.
• Life-threatening or uncontrolled medical illness unrelated to cancer.
• Ongoing nausea or vomiting that is Grade 2 or worse in intensity.
• Diarrhea that is Grade 2 or worse in intensity or use of an antimotility agent to control diarrhea to an intensity of Grade 1 or lower level.
• Known GI disease or GI procedures that could interfere with the oral absorption, excretion, or tolerance of alisertib.
• History of urinary and/or fecal incontinence.
• History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease.
• Inability to swallow tablets, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medications for 2 hours before and 1 hour after the first dose of alisertib.
• Inadequate bone marrow or other organ function as specified in study protocol.
• Any cardiovascular condition specified in the study protocol.
• Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
• Inability to comply with study visits and procedures including required inpatient confinement (approximately 11-17 days).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Comprehensive Clinical Development

Tacoma, Washington, United States

Countries

United States

Other Identifiers

U1111-1187-6760

Identifier Type: OTHER

Identifier Source: secondary_id

C14014

Identifier Type: -

Identifier Source: org_study_id